Last year, Andrea Rossi’s energy catalyzer, or E-Cat, created buzz as it claims to present an alternative energy source that is environmentally clean and free. The E-Cat is a cold fusion device that fuses hydrogen atoms with nickel to transform it into copper. The resulting fusion reaction creates heat that will drive a turbine, which would then generate electricity. Andrea Rossi and physicist Sergio Focardi demonstrated the device last October and the E-Cat produced an average of 470 kilowatts for more than five hours.
During our research on Rossi’s Energy Catalyzer, we came across the “acoustic inertial confinement” or sound drive fusion developed by Impuse Devices Inc., based in California. The company uses the process of acoustic cavitation, the use of acoustic field to expand and collapse tiny bubbles to generate hot temperatures. As the bubbles shrink, the pressure and temperature of the vapor increase, reaching their maximum upon bubble collapse. The temperature and pressure of the gas inside the cavities can exceed temperatures on the surface of the sun.
Regina’s new book ‘Soulo Journey: Life From the soul’s Perspective’ offers a rarely glimpsed rendering of the origins of the human species. With this new understanding of what it is to be a Human-Being, our choices change.
Empowering and enlightening, ‘Soulo Journey’ draws from Regina’s 30 year background in esoteric studies combined with having had access to more than 400 brilliant thinkers of our time as the host of Conscious Media Network.
Soulo Journey takes the fear out of understanding humanity’s deepest roots and reflects back our true entitlement to limitless creation.
The following are a few of the subjects covered:
How the human species came into creation
The schism of the soul vs. animal mind
Choosing our gene pool
Why humans have required outside ‘guidance’
Healing from the soul’s perspective
Human feedback loops with Earth
Manifesting from the Soul
Giving children voice
Breaking the hypnosis and unearthing our own truths
Read about 115 Sheriffs meeting in Los Vegas to hear about their role in defending the Constitution, as the only elected law enforcement in the nation.
Professor Chris Busby of the University of Ulster (GO Ireland!): Evidence suggesting that “Enriched” Uranium weapons (as opposed to depleted uranium antitank weapons which are bad enough) were used in Fallujah causing major birth defects, mutations and likely radioactive blowback contamination of US troops whose offspring now have high incidences of birth defects compatible with radiation poisoning of reproductive organs. Enriched uranium weapons are top secret and illegal because they are technically a poison gas and antipersonell weapons and therefore constitute international war crimes.
Mysterious deaths of US soldiers in Bagdad. NATO experts tend to believe result from direct exposure to powerful nuclear radiations of the sophisticated B-2 bombs used in the war on Iraq, particularly in striking Iraqi Republican Guards forces who deployed to defend the vicinity of Baghdad airport. Read more…
Morgellons is not a disease. It is a process. It is a form of forced/directed evolution of the human genome. It is the fetal stage of transhumanism, and it is upon us. This stealth project is being carried out with the use of the daily chemtrail operations, which are happening globally. There is no escape. The chemtrail operations are terraforming the earth and everything on it. Read more…
The Binary Biology enables the ecdysone switch to control populations.
Hormones served in food can turn the switch on, combine the two parts of
Binary Biological weapons already installed in people.
Yale and Stanford Universities Patents
Morgellons patents: US 6245531 Polynucleotides Encoding Insect Ecdysone Receptorhttp://www.patentlens.net/imageserver... US 5514578A Polynucleotides Encoding Insect Steroid Hormone Receptor Polypeptides and Cells Transformed With Same http://www.patentlens.net/patentlens/... Inventors: David Hogness, 650-723-6166, tran@cmgm.stanford.edu Michael Koelle, 203-432-5662, Michael.koelle@yale.edu William Seagraves, 203-432-4537, William.seagraves@yale.edu —————————————-—————————————- SPRING HOUSE, Pa.–(BW HealthWire)–May 7, 2002 Agreement grants Invitrogen nonexclusive, worldwide rights to manufacture and sell Ecdysone-Inducible Expression research kits RHeoGene today announced it has egotiated an agreement to grant Invitrogen (Carlsbad, CA) a nonexclusive, worldwide sublicense for sales of Invitrogen’s Ecdysone-Inducible Expression System and related products for research purposes only. RHeoGene holds an exclusive license to Stanford University patents U.S. 5,514,578, 6,245,531 and EP Patent 0517805 that cover sales and use of certain ecdysone-based products. Invitrogen has been manufacturing and selling its Ecdysone- Inducible Expression System under a separate license since 1996. Under its license from RHeoGene, Invitrogen will continue to provide Ecdysone-Inducible Expression System products to academic, government, industrial, and clinical institutions for research purposes. Customers wishing to use ecdysone receptor-based gene expression systems for commercial purposes should contact RHeoGene for a commercial license. “This licensing agreement is the first external validation of the importance of RHeoGene’s exclusive license to the intellectual property encompassed by these Stanford patents after broader claims to U.S. 5,514,578 were granted,” said Tom Tillett, RHeoGene Executive Vice President for Operations. The Stanford patents are directed to genes that encode insect-based ecdysone receptors from a broad range of insect species and methods for regulating gene expression in host cells. The patent coverage includes ecdysone receptor (EcR) genes originating from Drosophila, the basis of Invitrogen’s Ecdysone-Inducible Expression System. The patents are based on the pioneering research of Dr. David Hogness, Emeritus Munzer Professor of Developmental Biology and Biochemistry at Stanford University. RHeoGene’s exclusive license to these patents encompasses all uses outside of plants, including cell-based assays, genomics, proteomics, gene therapy, cell culture/fermentation, transgenic animals, and biosensors. RHeoGene focuses on delivering customized inducible gene expression technology systems to advance proteomics, drug discovery, biotherapeutics production, and human gene therapy. RHeoGene’s operations are located in Spring House, Pa., and Charlottesville, Va. For more information, visit www.rheogene.com.
Last year, Andrea Rossi’s energy catalyzer, or E-Cat, created buzz as it claims to present an alternative energy source that is environmentally clean and free. The E-Cat is a cold fusion device that fuses hydrogen atoms with nickel to transform it into copper. The resulting fusion reaction creates heat that will drive a turbine, which would then generate electricity. Andrea Rossi and physicist Sergio Focardi demonstrated the device last October and the E-Cat produced an average of 470 kilowatts for more than five hours.
